診斷藥的流通交易(2016年～2025年)

本報告提供生物醫藥品產業調查分析，2016年～2025年的診斷藥的流通交易相關，支付條件等詳細資訊。

目錄

摘要整理

第1章 簡介

第2章 流通交易趨勢

• 簡介
• 流通交易定義
• 流通交易趨勢(2016年以後)
  • 流通交易:各年度(2016年～2025年)
  • 流通交易:各開發階段(2016年～2025年)
  • 流通交易:各治療領域(2016年～2025年)
  • 流通交易:各技術類型(2016年～2025年)
  • 流通交易:最活躍的各企業(2016年～2025年)
• 簽訂流通合作夥伴交易的理由

第3章 流通交易結構概要

• 簡介
• 流通交易結構

第4章 主要流通交易

• 簡介
• 前幾名的流通交易(金額)

第5章 最活躍的流通交易企業前25名公司

• 簡介
• 最活躍的流通交易企業前25名公司
• 交易名錄
• 交易名錄 - 流通交易:各企業(A～Z)
• 交易名錄 - 流通交易:各治療領域
• 交易名錄 - 流通交易:各技術類型
• 關於Biopharma Research
• Current Partnering
• Current Agreements
• Current Partnering的近幾年的報告標題

Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2016 to 2025.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Diagnostics provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Diagnostics is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Diagnostics includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering diagnostics
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Diagnostics, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Diagnostics provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deal
• 2.3. Trends in distribution deals since 2016
  • 2.3.1. Distribution dealmaking by year, 2016-2025
  • 2.3.2. Distribution dealmaking by phase of development, 2016-2025
  • 2.3.3. Distribution dealmaking by therapy area, 2016-2025
  • 2.3.4. Distribution dealmaking by technology type, 2016-2025
  • 2.3.5. Distribution dealmaking by most active company, 2016-2025
• 2.4. Reasons for entering into distribution partnering deals

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2016 to 2025
• Figure 3: Distribution deals signed at each phase of development, 2016 to 2025
• Figure 4: Distribution deals by therapy area, 2016 to 2025
• Figure 5: Distribution deals by technology type, 2016 to 2025
• Figure 6: Top 25 most active distribution dealmakers, 2016 to 2025
• Figure 7: Issues in implementing distribution agreements
• Figure 8: Distribution agreements - what should a contract include?
• Figure 9: Components of the distribution deal structure
• Figure 10: Top distribution deals by value 2016 to 2025
• Figure 11: Most active distribution dealmakers 2016 to 2025